Search

Author/Creator Mahave, Mauricio

1. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227. Issue 6 (20th February 2023)

Authors:
Brahmer, Julie R.; Lee, Jong-Seok; Ciuleanu, Tudor-Eliade; Bernabe Caro, Reyes; Nishio, Makoto; Urban, Laszlo; Audigier-Valette, Clarisse; Lupinacci, Lorena; Sangha, Randeep; Pluzanski, Adam; Burgers, Jacobus; Mahave, Mauricio; Ahmed, Samreen; Schoenfeld, Adam J.; Paz-Ares, Luis G.; Reck, Martin;...
Journal:
Journal of clinical oncology
Issue:
Volume 41:Issue 6(2023)
Page Start:
1200
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022)

Authors:
Powles, Thomas; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N; Hajek, Jaroslav; Gurney, Howard; Chang, Yen-Hwa; Lee, Jae Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B; Sawrycki, Piotr; Burgents, Jo...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 9(2022)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search